CTX001, developed by Vertex Pharmaceuticals in collaboration with CRISPR Therapeutics, represents a significant advancement in the treatment of β-thalassemia and sickle cell disease (SCD). The long-term follow-up study aims to evaluate the safety and efficacy of CTX001 in patients previously treated in parent studies. The market for gene therapies targeting hematologic diseases is expanding, with increasing demand for innovative treatments that provide durable responses and reduce the need for transfusions. Competitive landscape includes other gene therapies and emerging CRISPR-based treatments, necessitating diligent monitoring of clinical outcomes and market positioning. The successful demonstration of long-term efficacy and safety could enhance market access and reimbursement opportunities, positioning CTX001 as a leading therapeutic option in this niche but critical market.